Surufatinib: First Approval
Sign Up to like & getrecommendations! Published in 2021 at "Drugs"
DOI: 10.1007/s40265-021-01489-y
Abstract: Surufatinib (Sulanda®), an oral angio-immuno kinase inhibitor that selectively targets VEGFR 1, 2, and 3, FGFR1 and CSF-1R, is being developed by HUTCHMED for the treatment of solid tumours, including neuroendocrine tumours (NETs). On 30… read more here.
Keywords: first approval; extrapancreatic net; surufatinib first; surufatinib ... See more keywords